Integrated Cell and Bioprocess Engineering for Rapid and Intensive Continuous Production of Biopharmaceuticals.
This project is concerned with the design and development of radically different new approaches to efficiently manufacture next generation recombinant protein biopharmaceuticals using engineered mammalian cells in culture. Historically, these medicines are made by genetically engineered cells grown in large-scale batch culture, where the complex protein product is subsequently harvested and purified in separate operations prior to formulation as a drug. Continuous bioproduction (CB) processes, which integrate both upstream (cell culture) and downstream (product capture and purification) operations offer significant potential advantages over traditional (fed-)batch based processes as they enable significant intensification and simplification of bioprocesses. In this project we will design new, disruptive technologies for CB that will seamlessly integrate discrete cell line engineering and upstream process development functions to create a novel biopharmaceutical biomanufacturing process development paradigm for CB.
This project is a collaboration between the University of Sheffield and the new National Biologics Manufacturing Centre (NBMC) at Darlington. The NBMC can offer a wide range of training and development opportunities for the student, where they will be fully integrated and included in all staff activities and have the same career development opportunities as other employees.
Applicants should have or expected to gain an Honours Degree, with a degree result of 2i or above, in a relevant bioscience or chemical/biological engineering subject.
This project is funded by EPSRC Case Award with Industrial partner, providing fees and stipend for UK candidates, and fees only for EU candidates.
Note that Overseas candidates are not eligible for this funding.